Skip to Main Navigation
Skip to Page Content

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/12447

Glycidol: Target Organs and Levels of Evidence for TR-374

Toxicology and Carcinogenesis Studies of Glycidol (CASRN 556-52-5) In F344/N Rats and B6C3F1 Mice (Gavage Studies)

Chemical (Study Title)
CASRN
Peer Review DateRoute/Exposure LevelsStudy Laboratory
Glycidol
556-52-5
06/27/1989Gavage
R: 0,38,75, M: 0,25,50 MG/KG/50 PER GROUP
Papanicolaou Research Institute

Levels of Evidence

Male Rats: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Mesothelium (Abdominal Cavity/Tunica Vaginalis): MESOTHELIOMA 3/50 34/50 39/50
  • Mammary Gland: FIBROADENOMA 3/50 8/50 7/50
  • Brain: GLIOMA 0/50 5/50 6/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 1/50 5/50 OR SQUAMOUS CELL CARCINOMA 1/50 1/50 2/50 COMBINED 1/50 2/50 6/50
  • Large Intestines: ADENOMATOUS POLYP 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 1/50 3/50 COMBINED 0/50 1/50 4/50
  • Skin: SEBACEOUS GLAND ADENOMA 0/50 0/50 1/50, BASAL CELL CARCINOMA 0/50 4/50 2/50, OR SEBACEOUS GLAND ADENOCARCINOMA 0/50 0/50 1/50 COMBINED 0/50 5/50 4/50
  • Zymbal Gland: CARCINOMA 1/50 3/50 6/50
  • Thyroid Gland Follicular Cell: ADENOMA 0/50 2/50 2/50 OR CARCINOMA 1/50 2/50 5/50 COMBINED 1/50 4/50 6/50
Non-Neoplastic Lesions
  • FORESTOMACH: HYPERKERATOSIS 3/50 13/50 15/50; DYSPLASIA, EPITHELIAL 0/50 10/50 8/50
  • SPLEEN: FIBROSIS 13/50 34/50 28/50
Female Rats: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Mammary Gland: FIBROADENOMA 14/50 32/50 29/50; ADENOCARCINOMA 1/50 11/50 16/50
  • Brain: GLIOMA 0/50 4/50 4/50
  • Oral Cavity: SQUAMOUS CELL PAPILLOMA 1/50 3/50 6/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 1/50 3/50 7/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 4/50 8/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 3/50 COMBINED 0/50 4/50 11/50
  • Clitoral Gland: ADENOMA 3/50 7/50 7/50, ADENOCARCINOMA 0/50 1/50 0/50, OR CARCINOMA 2/50 1/50 5/50 COMBINED 5/50 9/50 12/50
  • Thyroid Gland Follicular Cell: ADENOMA 0/50 1/50 0/49 OR CARCINOMA 0/50 0/50 3/49 COMBINED 0/50 1/50 3/49
  • Hematopoietic System: LEUKEMIA 13/50 14/50 20/50
May Have Been Related
  • Glandular Stomach: FIBROSARCOMA 0/50 0/50 2/50
Non-Neoplastic Lesions
  • FORESTOMACH: HYPERKERATOSIS 1/50 16/50 13/50; DYSPLASIA, EPITHELIAL 0/50 12/50 10/50
  • SPLEEN: FIBROSIS 3/50 14/49 20/50
Male Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Harderian Gland: ADENOMA 7/50 10/50 16/50 OR ADENOCARCINOMA 1/50 2/50 7/50 COMBINED 8/50 12/50 22/50
  • Forestomach: SQUAMOUS CELL PAPILLOMA 0/50 2/50 9/50 OR SQUAMOUS CELL CARCINOMA 1/50 0/50 1/50 COMBINED 1/50 2/50 10/50
  • Skin: SQUAMOUS CELL PAPILLOMA 0/50 0/50 4/50
  • Liver: ADENOMA 18/50 16/50 30/50 OR CARCINOMA 10/50 17/50 8/50 COMBINED 24/50 31/50 35/50
  • Lung: ALVEOLAR/BRONCHIOLAR ADENOMA 6/50 6/50 8/50 OR ALVEOLAR/BRONCHIOLAR CARCINOMA 7/50 5/50 14/50 COMBINED 13/50 11/50 21/50
May Have Been Related
  • Urinary Bladder: CARCINOMA 0/50 1/50 1/50
  • Epididymis: SARCOMA 0/50 0/50 2/50
Non-Neoplastic Lesions
  • FORESTOMACH: HYPERKERATOSIS 3/50 8/50 7/50
  • PREPUTIAL GLAND: CYST 1/50 0/50 7/50
  • KIDNEY: CYST 4/50 11/50 9/50
Female Mice: Clear Evidence
TypeOrgan/Tissue (Lesion)
Neoplastic Lesions
  • Harderian Gland: ADENOMA 4/50 10/50 16/50 OR ADENOCARCINOMA 0/50 1/50 1/50 COMBINED 4/50 11/50 17/50
  • Mammary Gland: ADENOMA 0/50 1/50 0/50, FIBROADENOMA 1/50 0/50 0/50, OR ADENOCARCINOMA 1/50 5/50 15/50 COMBINED 2/50 6/50 15/50
  • Uterus/Cervix: CARCINOMA 0/50 0/50 1/50 OR ADENOCARCINOMA 0/50 3/50 2/50 COMBINED 0/50 3/50 3/50
  • Subcutaneous Tissue: SARCOMA 0/50 1/50 6/50 OR FIBROSARCOMA 0/50 2/50 3/50 COMBINED 0/50 3/50 9/50
  • Skin: SQUAMOUS CELL PAPILLOMA 0/50 0/50 1/50 OR SQUAMOUS CELL CARCINOMA 0/50 0/50 1/50 COMBINED 0/50 0/50 2/50
Non-Neoplastic Lesions
  • FORESTOMACH: HYPERKERATOSIS 5/50 3/50 11/50